Kris Vinckier is a Director and Co-Founder of Paradox Investment Management BV, which manages the investment fund, Paradox Investment Network BV, a Private Privak under Belgian Law. Mr. Vinckier is a seasoned executive in the financial and commercial services sector, who currently serves as the Head of Business Strategy Life and Employee Benefits for Vivium, …
Dr. Kerry Maguire is a healthcare executive who most recently served as the Vice-President for Clinical Operations at the Forsyth Institute in Cambridge, MA. As a public health professional, her focus has been on health disparities of vulnerable populations, primarily children and people living with HIV. Kerry has held faculty roles at Tufts University School …
ASSOCIATE RESEARCHER Successful candidate will have prior experience with varied biochemical analytical methods such as ELISA and HPLC. This role will work in a team with Research Scientists in the conduct of key activities directed toward the development of the therapeutic pipeline products. RESPONSIBILITIES: General laboratory support activities including ordering supplies, maintenance of equipment and …
NORTH BRUNSWICK, N.J., January 24, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, reports highlights from its recent shareholder meeting. Highlights Include: Clinical: Completed second clinical study in the EU and planning US phase 2/3 program …
NORTH BRUNSWICK, N.J., October 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announces that it was selected to present at the MACRO Trends Investor Conference on November 12, 2021. Co-founders Valerie Ceva, COO, and …
BioAegis co-founders were selected to present at the upcoming MACRO Trends Investors Conference in Belgium. The presentation, “Conquering Pneumonia and Systemic Inflammation,” will highlight BioAegis’ novel, host-directed treatment. About MACRO Trends MACRO Trends is a Dutch Investment advisory firm centered around a regularly published magazine edited by Brecht Arnaert, a monetary expert at the Rey …
November 12, 2021: Belgium MACRO Trends Investors Conference Read More »
This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype. NORTH BRUNSWICK, N.J., September 28, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a previously unknown …
Reshma Kumari Sharma, Binita Goswami, Sukhen Das Mandal, Abhishek Guha, Belinda Willard and Partho Sarothi Ray (2021, August 6). Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in MacrophagesJ Immunol August 6, 2021, ji2001392; DOI: https://doi.org/10.4049/jimmunol.2001392 Abstract Quorum-sensing mechanisms that sense the density of immune cells at the site of inflammation to initiate inflammation resolution have recently been …
Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., August 27, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a case study, Recombinant Human Plasma Gelsolin (rhu-pGSN) in a Patient Hospitalized …
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced that it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant …
LOCATION:
BioAegis Therapeutics
North Brunswick, NJ
MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com
INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com
©2023 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use